AGIOS PHARMACEUTICALS, INC. Operating Expenses
AGIOS PHARMACEUTICALS, INC. (AGIO) reported Operating Expenses of $135.08 million for the 3-month period ending 2019-09-30, per its 10-Q filed 2019-10-31.
Discontinued › Expense Statement › Operating Expenses
us-gaap:OperatingExpenses · last filed 2021-02-25
- AGIOS PHARMACEUTICALS, INC. operating expenses for the quarter ending 2019-09-30 was $135.08M, a 18.12% increase year-over-year.
- AGIOS PHARMACEUTICALS, INC. operating expenses for the quarter ending 2019-06-30 was $140.08M, a 23.57% increase year-over-year.
- AGIOS PHARMACEUTICALS, INC. operating expenses for the quarter ending 2019-03-31 was $127.71M, a 24.26% increase year-over-year.
- AGIOS PHARMACEUTICALS, INC. operating expenses for the quarter ending 2018-12-31 was $126.37M, a 26.46% increase year-over-year.
- AGIOS PHARMACEUTICALS, INC. operating expenses for fiscal 2018 was $456.87M, a 25.58% increase from fiscal 2017.
- AGIOS PHARMACEUTICALS, INC. operating expenses for fiscal 2017 was $363.81M, a 34.31% increase from fiscal 2016.
- AGIOS PHARMACEUTICALS, INC. operating expenses for fiscal 2016 was $270.88M, a 52.33% increase from fiscal 2015.
- AGIOS PHARMACEUTICALS, INC. operating expenses for fiscal 2015 was $177.82M, a 48.81% increase from fiscal 2014.
| Period end | Operating Expenses 3 month | Operating Expenses 6 month | Operating Expenses 9 month | Operating Expenses 12 month |
|---|---|---|---|---|
| 2019-09-30 | $135.08M 10-Q · filed 2019-10-31 | $275.17M derived: sum of 2 quarters · filed 2019-10-31 | $402.88M 10-Q · filed 2019-10-31 | $529.25M derived: sum of 4 quarters · filed 2021-02-25 |
| 2019-06-30 | $140.08M 10-Q · filed 2019-08-01 | $267.79M 10-Q · filed 2019-08-01 | $394.16M derived: sum of 3 quarters · filed 2021-02-25 | $508.52M derived: sum of 4 quarters · filed 2021-02-25 |
| 2019-03-31 | $127.71M 10-Q · filed 2019-05-02 | $254.08M derived: sum of 2 quarters · filed 2021-02-25 | $368.44M derived: sum of 3 quarters · filed 2021-02-25 | $481.80M derived: sum of 4 quarters · filed 2021-02-25 |
| 2018-12-31 | $126.37M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | $240.73M derived: sum of 2 quarters · filed 2021-02-25 | $354.09M derived: sum of 3 quarters · filed 2021-02-25 | $456.87M 10-K · filed 2021-02-25 |
| 2018-09-30 | $114.36M 10-Q · filed 2019-10-31 | $227.72M derived: sum of 2 quarters · filed 2019-10-31 | $330.50M 10-Q · filed 2019-10-31 | $430.43M derived: sum of 4 quarters · filed 2019-10-31 |
| 2018-06-30 | $113.36M 10-Q · filed 2019-08-01 | $216.14M 10-Q · filed 2019-08-01 | $316.07M derived: sum of 3 quarters · filed 2019-08-01 | $406.44M derived: sum of 4 quarters · filed 2019-08-01 |
| 2018-03-31 | $102.77M 10-Q · filed 2019-05-02 | $202.70M derived: sum of 2 quarters · filed 2019-05-02 | $293.08M derived: sum of 3 quarters · filed 2019-05-02 | $389.02M derived: sum of 4 quarters · filed 2019-05-02 |
| 2017-12-31 | $99.93M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-14 | $190.30M derived: sum of 2 quarters · filed 2019-02-14 | $286.25M derived: sum of 3 quarters · filed 2019-02-14 | $363.81M 10-K · filed 2019-02-14 |
| 2017-09-30 | $90.38M 10-Q · filed 2018-11-01 | $186.32M derived: sum of 2 quarters · filed 2018-11-01 | $263.88M 10-Q · filed 2018-11-01 | $343.93M derived: sum of 4 quarters · filed 2019-02-14 |
| 2017-06-30 | $95.95M 10-Q · filed 2018-08-02 | $173.50M 10-Q · filed 2018-08-02 | $253.56M derived: sum of 3 quarters · filed 2019-02-14 | $326.06M derived: sum of 4 quarters · filed 2019-02-14 |
| 2017-03-31 | $77.56M 10-Q · filed 2018-05-04 | $157.61M derived: sum of 2 quarters · filed 2019-02-14 | $230.11M derived: sum of 3 quarters · filed 2019-02-14 | $293.56M derived: sum of 4 quarters · filed 2019-02-14 |
| 2016-12-31 | $80.06M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-14 | $152.55M derived: sum of 2 quarters · filed 2019-02-14 | $216.00M derived: sum of 3 quarters · filed 2019-02-14 | $270.88M 10-K · filed 2019-02-14 |
| 2016-09-30 | $72.50M 10-Q · filed 2017-11-01 | $135.94M derived: sum of 2 quarters · filed 2017-11-01 | $190.82M 10-Q · filed 2017-11-01 | $237.94M derived: sum of 4 quarters · filed 2018-02-14 |
| 2016-06-30 | $63.45M 10-Q · filed 2017-08-08 | $118.32M 10-Q · filed 2017-08-08 | $165.44M derived: sum of 3 quarters · filed 2018-02-14 | $211.39M derived: sum of 4 quarters · filed 2018-02-14 |
| 2016-03-31 | $54.88M 10-Q · filed 2017-05-04 | $101.99M derived: sum of 2 quarters · filed 2018-02-14 | $147.95M derived: sum of 3 quarters · filed 2018-02-14 | $193.30M derived: sum of 4 quarters · filed 2018-02-14 |
| 2015-12-31 | $47.12M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-14 | $93.07M derived: sum of 2 quarters · filed 2018-02-14 | $138.42M derived: sum of 3 quarters · filed 2018-02-14 | $177.82M 10-K · filed 2018-02-14 |
| 2015-09-30 | $45.95M 10-Q · filed 2016-11-03 | $91.31M derived: sum of 2 quarters · filed 2016-11-03 | $130.70M 10-Q · filed 2016-11-03 | $172.07M derived: sum of 4 quarters · filed 2017-02-16 |
| 2015-06-30 | $45.35M 10-Q · filed 2016-08-08 | $84.75M 10-Q · filed 2016-08-08 | $126.11M derived: sum of 3 quarters · filed 2017-02-16 | $156.80M derived: sum of 4 quarters · filed 2017-02-16 |
| 2015-03-31 | $39.40M 10-Q · filed 2016-05-09 | $80.76M derived: sum of 2 quarters · filed 2017-02-16 | $111.45M derived: sum of 3 quarters · filed 2017-02-16 | $138.19M derived: sum of 4 quarters · filed 2017-02-16 |
| 2014-12-31 | $41.36M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-16 | $72.06M derived: sum of 2 quarters · filed 2017-02-16 | $98.80M derived: sum of 3 quarters · filed 2017-02-16 | $119.49M 10-K · filed 2017-02-16 |
| 2014-09-30 | $30.69M 10-Q · filed 2015-11-06 | $57.43M derived: sum of 2 quarters · filed 2015-11-06 | $78.13M 10-Q · filed 2015-11-06 | $97.11M derived: sum of 4 quarters · filed 2016-02-26 |
| 2014-06-30 | $26.74M 10-Q · filed 2015-08-07 | $47.44M 10-Q · filed 2015-08-07 | $66.42M derived: sum of 3 quarters · filed 2016-02-26 | $83.76M derived: sum of 4 quarters · filed 2016-02-26 |
| 2014-03-31 | $20.70M 10-Q · filed 2015-05-11 | $39.68M derived: sum of 2 quarters · filed 2016-02-26 | $57.02M derived: sum of 3 quarters · filed 2016-02-26 | $71.81M derived: sum of 4 quarters · filed 2016-02-26 |
| 2013-12-31 | $18.99M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-26 | $36.32M derived: sum of 2 quarters · filed 2016-02-26 | $51.12M derived: sum of 3 quarters · filed 2016-02-26 | $64.43M 10-K · filed 2016-02-26 |
| 2013-09-30 | $17.34M 10-Q · filed 2014-11-07 | $32.13M derived: sum of 2 quarters · filed 2014-11-07 | $45.45M 10-Q · filed 2014-11-07 | $58.22M derived: sum of 4 quarters · filed 2015-02-24 |
| 2013-06-30 | $14.79M 10-Q · filed 2014-08-07 | $28.11M 10-Q · filed 2014-08-07 | $40.89M derived: sum of 3 quarters · filed 2015-02-24 | $52.27M derived: sum of 4 quarters · filed 2015-02-24 |
| 2013-03-31 | $13.31M 10-Q · filed 2014-05-09 | $26.09M derived: sum of 2 quarters · filed 2015-02-24 | $37.47M derived: sum of 3 quarters · filed 2015-02-24 | $49.88M derived: sum of 4 quarters · filed 2015-02-24 |
| 2012-12-31 | $12.78M derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-24 | $24.16M derived: sum of 2 quarters · filed 2015-02-24 | $36.57M derived: sum of 3 quarters · filed 2015-02-24 | $48.10M 10-K · filed 2015-02-24 |
| 2012-09-30 | $11.38M 10-Q · filed 2013-11-07 | $23.79M derived: sum of 2 quarters · filed 2013-11-07 | $35.32M 10-Q · filed 2013-11-07 | |
| 2012-06-30 | $12.41M 10-Q · filed 2013-09-05 | $23.94M 10-Q · filed 2013-09-05 | ||
| 2011-12-31 | $38.47M 10-K · filed 2014-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |